367 related articles for article (PubMed ID: 30875076)
1. Comparative Stability Studies of Different Infliximab and Biosimilar CT-P13 Clinical Solutions by Combined Use of Physicochemical Analytical Techniques and Enzyme-Linked Immunosorbent Assay (ELISA).
Hermosilla J; Sánchez-Martín R; Pérez-Robles R; Salmerón-García A; Casares S; Cabeza J; Cuadros-Rodríguez L; Navas N
BioDrugs; 2019 Apr; 33(2):193-205. PubMed ID: 30875076
[TBL] [Abstract][Full Text] [Related]
2. Biosimilarity under stress: A forced degradation study of Remicade® and Remsima™.
Pisupati K; Benet A; Tian Y; Okbazghi S; Kang J; Ford M; Saveliev S; Sen KI; Carlson E; Tolbert TJ; Ruotolo BT; Schwendeman SP; Schwendeman A
MAbs; 2017 Oct; 9(7):1197-1209. PubMed ID: 28787231
[TBL] [Abstract][Full Text] [Related]
3. CT-P13 (Inflectra™, Remsima™) monitoring in patients with inflammatory bowel disease.
Schulze K; Koppka N; Lutter F; Brandhorst G; Schreiber S; Helwig U
Biologicals; 2016 Sep; 44(5):463-6. PubMed ID: 27435444
[TBL] [Abstract][Full Text] [Related]
4. A review of CT-P13: an infliximab biosimilar.
McKeage K
BioDrugs; 2014 Jun; 28(3):313-21. PubMed ID: 24723086
[TBL] [Abstract][Full Text] [Related]
5. Stability of infliximab solutions in different temperature and dilution conditions.
Tokhadze N; Chennell P; Le Basle Y; Sautou V
J Pharm Biomed Anal; 2018 Feb; 150():386-395. PubMed ID: 29287266
[TBL] [Abstract][Full Text] [Related]
6. Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases.
Braun J; Kudrin A
Immunotherapy; 2015; 7(2):73-87. PubMed ID: 25713985
[TBL] [Abstract][Full Text] [Related]
7. Stability study over time of clinical solutions of ziv-aflibercept prepared in infusion bags using a proper combination of physicochemical and functional strategies.
Hermosilla J; Pérez-Robles R; Salmerón-García A; Casares S; Cabeza J; Navas N
J Pharm Biomed Anal; 2021 Sep; 203():114209. PubMed ID: 34153938
[TBL] [Abstract][Full Text] [Related]
8. Physicochemical characterization of Remsima.
Jung SK; Lee KH; Jeon JW; Lee JW; Kwon BO; Kim YJ; Bae JS; Kim DI; Lee SY; Chang SJ
MAbs; 2014; 6(5):1163-77. PubMed ID: 25517302
[TBL] [Abstract][Full Text] [Related]
9. Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima.
Ben-Horin S; Yavzori M; Benhar I; Fudim E; Picard O; Ungar B; Lee S; Kim S; Eliakim R; Chowers Y
Gut; 2016 Jul; 65(7):1132-8. PubMed ID: 25897019
[TBL] [Abstract][Full Text] [Related]
10. Part 1: Physicochemical characterization of bevacizumab in undiluted 25 mg/mL drug product solutions: Comparison of originator with a biosimilar candidate.
Arvinte T; Palais C; Poirier E; Cudd A; Rajendran S; Brokx S; Dowd J
J Pharm Biomed Anal; 2019 Oct; 175():112742. PubMed ID: 31344647
[TBL] [Abstract][Full Text] [Related]
11. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study.
Park W; Yoo DH; Jaworski J; Brzezicki J; Gnylorybov A; Kadinov V; Sariego IG; Abud-Mendoza C; Escalante WJ; Kang SW; Andersone D; Blanco F; Hong SS; Lee SH; Braun J
Arthritis Res Ther; 2016 Jan; 18():25. PubMed ID: 26795209
[TBL] [Abstract][Full Text] [Related]
12. Assessing the Extended In-Use Stability of the Infliximab Biosimilar PF-06438179/GP1111 Following Preparation for Intravenous Infusion.
Vimpolsek M; Gottar-Guillier M; Rossy E
Drugs R D; 2019 Jun; 19(2):127-140. PubMed ID: 30810925
[TBL] [Abstract][Full Text] [Related]
13. Physicochemical and biological characterization of SB2, a biosimilar of Remicade® (infliximab).
Hong J; Lee Y; Lee C; Eo S; Kim S; Lee N; Park J; Park S; Seo D; Jeong M; Lee Y; Yeon S; Bou-Assaf G; Sosic Z; Zhang W; Jaquez O
MAbs; 2017; 9(2):364-382. PubMed ID: 28005456
[TBL] [Abstract][Full Text] [Related]
14. Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study.
Smits LJ; Derikx LA; de Jong DJ; Boshuizen RS; van Esch AA; Drenth JP; Hoentjen F
J Crohns Colitis; 2016 Nov; 10(11):1287-1293. PubMed ID: 27095751
[TBL] [Abstract][Full Text] [Related]
15. One-month stability study of a biosimilar of infliximab (Remsima
Vieillard V; Astier A; Sauzay C; Paul M
Ann Pharm Fr; 2017 Jan; 75(1):17-29. PubMed ID: 27659414
[TBL] [Abstract][Full Text] [Related]
16. Comparison of immunogenicity test methods used in clinical studies of infliximab and its biosimilar (CT-P13).
Kim JS; Kim SH; Kwon B; Hong S
Expert Rev Clin Immunol; 2015; 11 Suppl 1():S33-41. PubMed ID: 26395835
[TBL] [Abstract][Full Text] [Related]
17. Effect of Thermal and Shear Stressors on the Physical Properties, Structural Integrity and Biological Activity of the Anti-TNF-alpha Monoclonal Antibody, Infliximab.
Alsaddique JA; Pabari RM; Ramtoola Z
Curr Pharm Biotechnol; 2016; 17(10):905-14. PubMed ID: 27194359
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the Cross-reactivity of Antidrug Antibodies to CT-P13 and Infliximab Reference Product (Remicade): An Analysis Using Immunoassays Tagged with Both Agents.
Reinisch W; Jahnsen J; Schreiber S; Danese S; Panés J; Balsa A; Park W; Kim J; Lee JU; Yoo DH
BioDrugs; 2017 Jun; 31(3):223-237. PubMed ID: 28497221
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study.
Yoo DH; Prodanovic N; Jaworski J; Miranda P; Ramiterre E; Lanzon A; Baranauskaite A; Wiland P; Abud-Mendoza C; Oparanov B; Smiyan S; Kim H; Lee SJ; Kim S; Park W
Ann Rheum Dis; 2017 Feb; 76(2):355-363. PubMed ID: 27130908
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Clinical Outcomes After Switching from Remicade
Smits LJT; Grelack A; Derikx LAAP; de Jong DJ; van Esch AAJ; Boshuizen RS; Drenth JPH; Hoentjen F
Dig Dis Sci; 2017 Nov; 62(11):3117-3122. PubMed ID: 28667429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
